Connect with us

NEWS

Colorectal Cancer’s First Rise in 20 Years Hits Screened Adults

U.S. colorectal cancer rates rose in 2023 among well-screened adults in their 60s, a birth-cohort wave that screening has not fully offset.

Published

on

U.S. colorectal cancer rates rose in 2023 for the first time in more than 20 years, according to a National Cancer Institute data analysis. Caitlin Murphy, PhD, MPH, professor of pediatrics and public health sciences at the University of Chicago, and colleagues tracked SEER 21 registries, which cover 45.8% of the country, and found the age-adjusted rate climbed from 36.7 per 100,000 in 2022 to 38.3 per 100,000 in 2023.

The jump reached every five-year age group through 65 to 69, including adults who already get screened at high rates. That is a different problem from the young-onset story that has dominated the past decade, and it is the one clinics will feel as those birth years move into older adulthood.

U.S. Colorectal Cancer Rates Rose in 2023

The paper, U.S. adults, 2000 to 2023, appeared in NEJM Evidence on October 27, 2026. It was funded by the National Institutes of Health and the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research Ablon Scholars Program. Coauthors include Folasade P. May of UCLA, Sonia Kupfer of UChicago Medicine, Xin Hu of Emory University, and Samir Gupta of UC San Diego.

Murphy said it was the first overall increase in more than 20 years. The long slide had been one of the clearer wins in U.S. cancer control, and most of that win was credited to screening.

THE 2023 UPTICK IN SEER 21

  • 2000 rate: 55.2 cases per 100,000 (95% CI, 54.8 to 55.6).
  • 2022 rate: 36.7 per 100,000 (95% CI, 36.4 to 37.0).
  • 2023 rate: 38.3 per 100,000 (95% CI, 38.0 to 38.6), with incidence up 2.76% a year from 2021 to 2023.
  • Pattern: similar by sex, tumor site, stage, and race and ethnicity, through ages 65 to 69.

The authors tested whether leftover COVID disruptions could explain the 2023 figure. Screening had largely returned to pre-pandemic levels by January 2021, and the rise held even when 2020 and 2021 were pulled out of the series. A one-year catch-up in delayed colonoscopies is a weak fit for a change that runs across so many ages at once.

Why Rates Rose in Adults Who Already Get Screened

The steepest annual change sat in ages 45 to 49, where incidence rose 12.76% a year from 2019 to 2023. Murphy said that bump is what you would expect after national guidance moved the start of average-risk screening from 50 to 45. “That means that screening is doing as we intend it to do. It’s catching cancer earlier,” she said.

That explanation does not travel. Rates also rose in ages 65 to 69, and they flattened in ages 70 to 74. Those bands were the groups that gained the most when colonoscopy use spread, and about 80% of them are already up to date with screening. If screening were still driving the national rate down, this is where the decline should have held.

AGE GROUPS IN THE SEER 21 ANALYSIS

Age group Direction Period What the authors note
45 to 49 +12.76% a year 2019 to 2023 Likely extra screening after the start age fell to 45
65 to 69 -1.79% a year, then +2.73% a year 2011 to 2021, then 2021 to 2023 About 80% up to date with screening
70 to 74 Rates flattened Recent years Historically among the biggest gainers from screening
All ages 36.7 to 38.3 per 100,000; +2.76% a year 2022 to 2023; 2021 to 2023 First overall rise since SEER 21 began in 2000

Unknown risk factors appear to be offsetting screening’s gains in the older bands. That is the finding that should reframe the young-onset debate. The same force that lifted cases before age 50 is now visible in people who did the test on schedule.

The 1960s Birth Cohort Moves Into Its 60s

Murphy had expected this. Epidemiologists call it a birth cohort effect: people born in the 1960s and later carry a higher colorectal cancer risk than earlier generations did at the same age, and they take that extra risk with them as they grow older. Someone born in 1964 turned 59 in 2023. The leading edge of that group is now inside the ages where most colorectal cancers are found.

I think of a birth cohort effect as the interaction of age and time. As people born around the same time move through time and age together, we’re going to see more colorectal cancers being diagnosed.

Caitlin Murphy, professor of pediatrics and public health sciences, University of Chicago

She has argued for years that the under-50 rise was never a sealed-off disease of the young. “There are many unique challenges when you’re diagnosed with cancer at a young age, so it’s important that we shine a spotlight on that problem,” she said. “But in terms of understanding the root cause, I think our study shows that we can consider that whatever might be causing colorectal cancer in younger people is now also causing it to increase in older people as well.”

The loud public argument still treats the rise as a disease of people in their 20s, 30s, and 40s, and it often pins the cause on a single villain in the food supply. That fight has not absorbed the 65-to-69 result. A 2020 disruption also fits poorly with a risk that tracks birth years back to the 1960s.

158,850 New Cases Are Projected for 2026

The American Cancer Society’s Colorectal Cancer Statistics, 2026 report, published March 2, 2026, still reads as two trends because it is built on 2013 to 2022 incidence, a window that ends before the 2023 SEER uptick. ACS projects 158,850 new cases in 2026 and 55,230 deaths, including 108,860 colon tumors and 49,990 rectal tumors. Colorectal cancer remains the second leading cause of cancer death in the United States and the first in adults younger than 50.

In that 2013 to 2022 span, ACS found incidence up 3% a year in ages 20 to 49 and 0.4% a year in ages 50 to 64, while it fell 2.5% a year in ages 65 and older, for a 0.9% annual decline overall. People younger than 65 now account for 45% of new diagnoses, up from 27% in 1995. Rectal tumors are 32% of colorectal cancers, up from 27% in the mid-2000s.

ACS 2026 SNAPSHOT (2013 TO 2022 TRENDS)

  • Deaths under 50: up 1% a year since 2004, against falling death rates for breast, lung, and prostate cancer in that age band.
  • Deaths at 50 to 64: up 1% a year since 2019.
  • Deaths at 65 and older: down 2.3% a year since 2012.
  • Stage in the young: 3 in 4 cases before age 50 are regional or distant at diagnosis, and 27% are distant.

Ahmedin Jemal, DVM, PhD, senior vice president of surveillance, prevention, and health services research at ACS, said colorectal cancer can no longer be called an old person’s disease and called for research on generations born since 1950. His report and Murphy’s paper are not in conflict once the years are named. ACS averaged a decade in which 65-and-older rates were still falling. Murphy’s 2021 to 2023 turn in ages 65 to 69 is the first sign that those older-adult gains are stalling as the later birth years arrive.

Screening at 45 Still Misses Most Eligible Adults

Half of colorectal cancers diagnosed before 50 fall in ages 45 to 49, the first years of average-risk eligibility. Only 37% of people 45 to 49 are up to date with screening, ACS found. The National Colorectal Cancer Roundtable, using the National Health Interview Survey, put up-to-date screening among all adults 45 and older at 59% in 2021 and 65% in 2023, still short of its 80% goal. About 1.54 million people in the United States are alive with a history of the disease.

ACS moved its start age to 45 in 2018. The U.S. Preventive Services Task Force followed on May 18, 2021, with screening from age 45 as a B grade for ages 45 to 49, an A grade for ages 50 to 75, and a C grade for selective screening at 76 to 85. Uptake in the newly eligible band has been slow. A UCLA-led claims study found that after an abnormal blood-based screen, 49% of patients completed a follow-up colonoscopy within six months. May, a coauthor of the SEER paper, was senior author on that follow-up work. A positive stool or blood test only works if the colonoscopy happens.

What Tests the Task Force Lists for Average-Risk Adults

The CDC list of screening tests matches the Task Force menu. Several of the options can be done at home. A positive stool test, sigmoidoscopy, or CT colonography still needs a colonoscopy to finish the job.

TASK FORCE SCREENING OPTIONS

  • FIT or high-sensitivity gFOBT: stool test once a year.
  • Stool DNA-FIT: every 1 to 3 years.
  • CT colonography: every 5 years.
  • Flexible sigmoidoscopy: every 5 years, or every 10 years plus annual FIT.
  • Colonoscopy: every 10 years if risk is average and the exam is normal.

The 2021 Task Force statement does not include blood tests, urine tests, or capsule endoscopy. ACS added a blood-based option in May 2026, the Shield test from Guardant Health, which the Food and Drug Administration cleared in 2024, for average-risk adults 45 and older who have declined stool tests and visual exams. Gastroenterology groups have warned that blood tests miss most advanced precancerous growths, which colonoscopy can find and remove in the same visit.

There are several ways to do screening that should be discussed with a clinician, so people know what the different screening tests are intended for and how often these need to be repeated.

Sonia Kupfer, MD, director of the Gastrointestinal Cancer Risk and Prevention Clinic, UChicago Medicine

For people younger than 45 with no extra risk, Kupfer said the job is to treat symptoms as a reason to see a doctor, not to wait for a birthday. Blood in the stool, a change in bowel habits, and unexplained weight loss are the flags she named. People with inflammatory bowel disease, a personal or family history of colorectal cancer or polyps, or a syndrome such as Lynch syndrome or familial adenomatous polyposis may need to start earlier than 45.

Blood Samples and Dish-Grown Colons Come Next

The authors cannot yet name the exposure. Murphy and Hu plan to measure thousands of environmental chemicals at once in a small blood sample, then hand the suspects to Kupfer’s lab, which can grow colon tissue as organoids and watch what those chemicals do. That design treats the 1960s as a hinge in the chemical record, not only as a birth year.

A separate 2026 Nature Medicine analysis of tumor methylation and county pesticide data linked early-onset colorectal cancer to a herbicide registered in 1964, picloram, and reported weaker signals for glyphosate, atrazine, and other agents. That paper does not prove what drove the 2023 SEER rise. It does sit on the same timeline the birth-cohort reading implies: products and practices that entered wide use as those generations were children.

Other leads in the wider literature include diet, obesity, alcohol, smoking, sedentary time, early-life antibiotics, and colibactin-producing gut bacteria. None has been shown to account for the full age pattern in the new SEER series. Kupfer said the results should push that search, “so risk factors can be identified and possibly reduced.”

Murphy warned that if the trend holds, a large aging group with higher risk will mean more treatment and more care after treatment. Registry data update every year, and 2023 is one year. Until the chemicals are named, the Task Force still tells average-risk adults to start screening at 45 and continue through 75, and the 65-to-69 figures show that showing up for the test is no longer enough to keep the national rate falling.

Frequently Asked Questions

At What Age Should Average-Risk Adults Start Colorectal Cancer Screening?

The U.S. Preventive Services Task Force gives a B grade to screening at ages 45 to 49 and an A grade to screening at ages 50 to 75, and it gives a C grade to selective screening at ages 76 to 85 based on health, prior testing, and preference. ACS tells people in good health with more than 10 years of life expectancy to continue through 75 and to stop after 85. Insurance plans generally cover the recommended tests with no deductible or copay, though patients should confirm the specific test with their plan.

Do Blood Tests Replace a Colonoscopy?

No. ACS allows a blood test only for average-risk adults 45 and older who have not completed, or have declined, stool tests and visual exams, and the Task Force’s 2021 statement still omits serum tests. Any abnormal blood or stool result requires a colonoscopy to look for cancer or polyps. Blood tests also miss most advanced precancers, so they do not prevent cancer the way a colonoscopy can by removing polyps in the same visit.

What Is a Birth Cohort Effect in Colorectal Cancer?

It means risk tracks the decade of birth, not only current age. People born in the 1960s and later have higher colorectal cancer rates than people born earlier did when they were the same age, so the extra risk moves with them into their 50s and 60s. That is why a rise first described in adults under 50 can later appear in well-screened adults in their 60s without a new screening failure in that older group.

What Symptoms Should People Younger Than 45 Take Seriously?

Kupfer named blood in the stool, a change in bowel habits, and unexplained weight loss as reasons to see a clinician rather than wait until screening age. Rectal bleeding, abdominal pain, diarrhea, and iron-deficiency anemia are the red-flag symptoms ACS tells the public and clinicians to treat as diagnostic workups, not as a problem that can wait for a 45th birthday. People with family history or a genetic syndrome should ask about starting tests before 45 even if they feel well.

Disclaimer: This article is news reporting and analysis of published cancer-registry research and screening guidelines. It is informational only and is not medical advice, a diagnosis, or a personal screening plan. It does not tell any reader which test to take, when to start, or how to treat symptoms. Talk with a qualified physician or gastroenterologist before changing screening, ignoring symptoms, or making decisions about blood-based tests versus colonoscopy. Incidence figures, screening rates, and guideline grades reflect the cited sources as of this article’s date and can change as registries and task forces update their data.

Harry is the editor of COVER 365, an independent publication he owns and runs, and a journalist of ten years who moved from reporting into editing. Anything the site reviews has been used before it is judged. A phone, a car, a game or a piece of travel gear is tested in ordinary conditions, its measured results are set against the maker's specification sheet, and where the two disagree the article says which one to trust and why. No product gets a verdict Harry has not earned by using it. Off the test bench, the same rule of primary evidence applies: business stories come from filings and results, science from the published paper, sports from the governing body's records, and news from statements and transcripts rather than second hand accounts. Coverage runs across technology, auto, gaming, lifestyle and travel as well as news, business, science, sports and entertainment, for readers in every part of the world. Every figure is checked before publication and corrected publicly under a stated policy when wrong. Reader mail is answered at support@cover365.in.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending